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Background: Familial British and Familial Danish dementias (FBD and FDD, respectively) are associated with
mutations in the BRI2 gene. Processing of the mutated BRI2 protein leads to the accumulation in the brain of the
34-mer amyloid Bri (ABri) and amyloid Dan (ADan) peptides, accompanied by neurofibrillary tangles. Recently,
transgenic mice successfully reproduced different aspects of FDD, while modeling of FBD in vivo has been more
difficult. In this work we have modeled FBD and FDD in Drosophila and tested the hypothesis that ABri and ADan
are differentially neurotoxic.
Results: By using site-directed insertion, we generated transgenic lines carrying ABri, ADan, Bri2-23 (the normal
product of wild-type BRI2 processing) and amyloid-β (Aβ) 1–42 as a well-characterized neurotoxic peptide, alone
or with a His-tag. Therefore, we avoided random insertion effects and were able to compare levels of accumulation
accurately. Peptides were expressed with the GAL4-Upstream Activating Sequence (UAS) system using specific
drivers. Despite low levels of expression, toxicity in the eye was characterized by mild disorganization of ommatidia
and amyloid peptides accumulation. The highest toxicity was seen for ADan, followed by Aβ42 and ABri.
Pan-neuronal expression in the CNS revealed an age-dependent toxicity of amyloid peptides as determined by the
ability of flies to climb in a geotaxis paradigm when compared to Bri2-23. This effect was stronger for ADan,
detected at 7 days post-eclosion, and followed by ABri and Aβ42, whose toxicity became evident after 15 and 21
days, respectively. Histological analysis showed mild vacuolization and thioflavine-S-negative deposits of amyloid
peptides. In contrast, the over-expression of amyloid peptides in the specific subset of lateral neurons that control
circadian locomotor activity showed no toxicity.
Conclusions: Our results support the differential neurotoxicity of ADan and ABri in the Drosophila eye and CNS at
low expression levels. Such differences may be partially attributed to rates of aggregation and accumulation. In the
CNS, both peptides appear to be more neurotoxic than wild-type Aβ42. These Drosophila models will allow a
systematic and unambiguous comparison of differences and similarities in the mechanisms of toxicity of diverse
amyloid peptides associated with dementia.
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Familial British Dementia (FBD) and Familial Danish
Dementia (FDD) are autosomal dominant neurodegene-
rative disorders associated with mutations in the BRI2
gene on chromosome 13 (also named ITM2B) [1,2].
FBD usually starts in the fifth decade of life with pro-
gressive dementia, spasticity and ataxia leading to death
in ~9 years [3]. FDD starts earlier, before 30 years of age
with cataracts, visual loss followed by impaired hearing,
progressive cerebellar ataxia and late dementia. Patients
die within the sixth-seventh decade of life [4]. A promin-
ent neuropathological finding in FBD and FDD patients
is the accumulation of amyloid proteins in the walls of
small arteries with a widespread distribution. This in-
cludes the cerebral cortex, leptomeninges, cerebellum,
brain stem and white matter [5,6]. In addition, parenchy-
mal amyloid deposits and neurofibrillary tangles are con-
sistently found with a notorious and severe compromise
of the hippocampus. In this regard, FBD and FDD (to-
gether with some cases of hereditary prionoses) are
closely similar to Alzheimer’s disease (AD), the major
cause of dementia in aging populations. A further simi-
larity between FBD, FDD and AD is that amyloid de-
posits are made of short peptides generated in the brain
by internal proteolysis of larger transmembrane precur-
sor proteins. These peptides of ~4 kDa, are: amyloid β
(Aβ) in AD [7,8], ABri in FBD and ADan in FDD [1,2].
In FBD, a missense mutation at the BRI2 stop codon
leads to the generation of the ABri peptide sequence [1].
In FDD, a 10-nucleotide duplication insertion causes a
frame shift and the generation of the ADan sequence
[2]. Both 34-residue peptides (ABri and ADan) and the
normal peptide product of wild-type BRI2 (Bri2-23) are
released by furin and other subtilisin/kexin-like pro-
protein convertases (PCs) by cleavage of the BRI2 carboxyl-
terminus along the secretory pathway [9].
Processing of BRI2 seems to be complex, involving sev-
eral proteases in addition to PCs. The pro-protein and
mature BRI2 (m-BRI2) protein may also be cleaved by a
disintegrin and metalloproteinase domain-containing pro-
tein 10 (ADAM10), releasing the Brichos domain [10] and
an N-terminal fragment (NTF). The NTF is also the sub-
ject of additional proteolysis by signal peptide peptidase-
like 2 (SPPL2), releasing an intracellular domain (ICD)
and the BRI2 C-peptide (Figure 1) [11]. To date, the bio-
logical roles of BRI2 and the pro-peptide Bri2-23 have not
been elucidated. In vitro studies showed that oligomers of
ABri and ADan are toxic to neuronal cell lines [12,13].
Recently, transgenic mouse models for FDD have been
generated. The first reported line carries a mutant BRI2
under the mouse prion protein promoter and after 6
months of age shows extensive vascular deposition, par-
enchymal ADan accumulation, gliosis and an increase of
phosphorylated-tau immunoreactivity [14]. When thistransgenic animal was crossed with tau-P301S transgenic
mice (Tg-Tau P301S), there was an increase of tau accu-
mulation, phosphorylation and caspase cleavage of tau at
Asp421 [15]. A knock-in (KI) mouse, carrying the FDD
mutation in endogenous BRI2 has also been generated al-
though it did not show detectable brain abnormalities
[16]. In addition, two other transgenic lines that over-
express BRI2 containing the FDD mutation have been pro-
duced [17]. The FDD-like line with higher expression
displays ADan accumulation in the hippocampus and
meningeal vessels after 2 months of age with a marked
age-dependent increase in amyloid deposition, particularly
in the microvasculature. In addition, when crossed with
Tg-tau P301S mice, these animals show a significant incre-
ment in the accumulation of hyperphosphorylated tau as
compared to the Tg-tau P301S alone. Therefore, mouse
models of FDD that overexpress mutant BRI2 in the brain
recapitulate several key features of the human disease.
Regarding FBD, the development of a transgenic ani-
mal model reproducing basic lesions of the disease has
been more elusive. Lines of transgenic mice carrying the
FBD mutation have been generated and despite high
levels of mutant BRI2 expression, no brain pathology
was detected. Moreover, ABri peptide did not accumu-
late in the brain and only minimal amounts were de-
tected by immunoprecipitation even after exogenous
furin overexpression [18]. A second approach, using the
KI strategy, showed that mice carrying the FBD muta-
tion in one mouse BRI2 allele developed a significant
deficit in hippocampal-dependent memory tasks by the
age of 9 months without neuropathology or ABri depos-
ition [19]. However, a reduction in BRI2 was detected in
synaptic vesicles as compared to wild-type mice. These
results together with the finding of similar memory defi-
cits in BRI2 haplo-deficient mice (Bri2
+/−) and lower
levels of BRI2 in FBD brains has led to the hypothesis
that loss of function of BRI2 may be a contributing fac-
tor to the development of dementia in FBD patients
[19]. Other studies have reported that BRI2 may modu-
late amyloid β precursor protein (AβPP) processing in
transfected cells and in transgenic mice leading to a re-
duced Aβ production and aggregation [20,21].
Drosophila melanogaster has been extensively used to
reproduce basic aspects of several neurodegenerative
diseases including AD, Parkinson disease, frontotem-
poral dementia, polyglutamine diseases, non-coding tri-
nucleotide repeat expansion disease, amyotrophic lateral
sclerosis and prion diseases [22-25]. The first fly model
for AD was designed to over-express human AβPP, hu-
man β-secretase and presenilin1 mutants associated with
familial AD. These animals showed Aβ accumulation
and shortened life span [26]. Other groups have gener-
ated transgenic flies targeting Aβ directly to the
secretory pathway. These flies developed age-dependent
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Figure 1 Proteolytic processing of BRI2. Schematic diagram representing the proteolytic events of BRI2 processing. Proprotein convertases (PC)
release a C-terminal 23-residue peptide (Bri2-23). Cleavage by ADAM10 of the BRI2 ectodomain releases the Brichos domain to the extracellular
space and leaves an N-terminal fragment (NTF) attached to the membrane. NTF is further processed by signal peptide peptidase-like 2 (SPPL2)
generating an intracellular domain (ICD) and an extracellular BRI2 –C-terminal peptide (BRi2−C peptide). Instead of Bri2-23, cleavage of the mutant
BRI2 by PC releases ABri in FBD or ADan in FDD, respectively (not depicted). im-BRI2, immature BRI2; m-BRI2, mature BRI2. Glyc, glycosylation; TM,
trans-membrane; ICD, intracellular domain.
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ied by defects in locomotion, memory and learning
[27-30]. Further studies of these lines showed that Aβ
caused defects in axonal transport, synaptic integrity and
mitochondrial mislocalization [31-33].
In this study we report the generation and char-
acterization of transgenic flies that over-express ABri,
ADan and the normal product of BRI2, Bri2-23, by site-
directed insertion. For comparison, a line expressing Aβ1-
42 was also generated. Although the toxicity of wild-type
Aβ and Aβ mutants in flies has been extensively described
[26-41], the strategy used in this study included Aβ as a
reference for comparison with ABri and ADan, for which
no Drosophila models have been reported. Our results
support the neurotoxicity of both FBD and FDD-
associated peptides in contrast to Bri2-23. In addition, im-
portant differences were appreciated in terms of degree of
toxicity and vulnerability of neuronal types. Moreover,
this is the first report of the toxic effects of ABri expres-
sion in an animal model.
Results and discussion
Generation of transgenic lines
To examine and compare the effects of ABri, ADan and
Aβ42 over-expression in Drosophila, we generated trans-
genic lines carrying the sequence of each amyloid pep-
tide fused to the signal peptide of Drosophila Necrotic
(Nec) that targets the protein to the secretory pathway
This strategy has been used successfully with Aβ [29]
and circumvents possible difficulties due to an insuffi-
cient processing of BRI2 (particularly in the case of ABri,
as suggested by the mouse models). To avoid positional
effects associated with random insertion in the genome,we used the φ-recombinase-based system [42] to direct
insertion of transgenes at a specific site on chromosome
3. Since there are no specific antibodies to Bri2-23, we
generated a set of constructs with a 6 x His-tag at their
amino-termini (Additional file 1). This allowed us to
compare the levels of accumulation of each peptide by
using the same antibody. All the peptides designed in
this study are schematically shown in Figure 2A. PCRs
with specific primers were used to assess the insertion of
the correct cDNAs (Figure 2B). The “site-directed” stra-
tegy allows a better comparison of the effect caused by
each peptide because the levels of mRNA expression
should be similar. Accordingly, Quantitative Real-Time
PCR (QRT-PCR) using the same set of primers showed no
significant differences in the expression levels of Bri2-23,
ABri and ADan mRNAs (Figure 2C).
Expression and processing of Bri2-23, Aβ42, ABri
and ADan
To examine whether the fusion peptides were correctly
targeted and cleaved to release two copies of Bri2-23,
Aβ42, ABri and ADan, peptides were expressed in the
eye using the Glass Multiple Reporter (GMR-GAL4)
driver and the GAL4-UAS bipartite system. Ten days
post-eclosion (p.e), homogenates from transgenic and
control fly heads were analyzed by Western blots. In the
GMR-GAL4/HisBri2-23 line, anti-His showed a very faint
band of ~3 kDa (at the limit of detection) compatible
with a properly processed Bri2-23 (Figure 3A). The Aβ42
monomer was clearly detected with monoclonal 6E10
antibody (Figure 3B). Regarding ABri, a specific band
with the size of a monomer was detected with anti-ABri
antibody (Figure 3C). The processing of ADan was
B1- nec -DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA (Aβ42)
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Figure 2 Generation of transgenic lines with similar expression levels. A, schematic representation of the fusion peptides used to generate
transgenic flies. Amino-acid single-letter code is used. Nec, the signal peptide of necrotic (MASKVSILLLLTVHLLAAQTFAQ); (H)6 indicates the 6 ×
His-tag. The arrow indicates the site of cleavage in the secretory pathway. The rectangle encloses the sequence shared by Bri2-23, ABri and ADan.
B, agarose gels showing the PCR products obtained from genomic DNA of transgenic lines carrying one copy of untagged (arrowheads) or two
copies: one untagged and the other with a 6 × His-tagged peptide DNAs (arrows). On the right, molecular markers in base-pairs (bp). C, similar
levels of mRNA expression of Bri2-23, ABri and ADan in the eye as determined by QRT-PCR normalized with tubulin mRNA. Bars represent the
mean ± SEM of 3 independent experiments. A.U., arbitrary units.
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http://www.molecularneurodegeneration.com/content/9/1/5assessed with a specific antibody directed to the peptide
carboxyl-terminus, which showed a 4 kDa band consis-
tent with ADan monomer (Figure 3D). It is of note that
differently from other reports using Aβ-transgenic Dros-
ophila, mouse models of ADan or brain tissue from FBD
and FDD patients, no SDS-resistant high order oligo-
meric species were detected in our transgenic lines
(Additional file 2). In addition, the bulk of amyloid pep-
tides were solubilized in buffer containing 1% Triton X-
100 and 1% SDS, while only traces of Aβ42 and ADan
remained as a formic-soluble fraction (Additional file 2).
These results suggest that the proteins are correctly
processed along the secretory pathway, generating
mostly soluble peptides with small amounts of insoluble
aggregates.
Toxicity of Aβ42, ABri and ADan in the eye
At 10 days p.e, eyes were morphologically examined for
toxicity by light microscopy and scanning electron mi-
croscopy (ESEM). When one or two copies of Aβ42,
ABri and ADan were expressed in the eye using GMR-
GAL4 and flies maintained at 25°C, no toxic effects were
detected (not shown). By raising temperature to 28°C, an
expected mild toxicity was seen in heterozygous GMR-
GAL4/+ lines, as reported [43]. However, such effect was
greatly reduced in the GMR-GAL4/Bri2-23 line, likely
due to titration of free GAL4 to the UAS repeats avail-
able for GAL4 binding (Additional file 3). Therefore, weused GMR-GAL4/Bri2-23 as a control to compare the ef-
fects of Aβ42, ABri and ADan expression. The eyes from
GMR-GAL4/Bri2-23 flies showed few scattered omma-
tidia of different sizes, but this defect was much lower
than the disorganization seen in the amyloid-expressing
lines. Light microscopy (not shown) and ESEM micro-
graphs revealed a pattern of ommatidia disarray in the
amyloid- expressing eyes related to BRI2-23 (Figure 4A).
The penetrance of these phenotypes was 90-100% in all
cases. Since the phenotype was mild, the extent of tox-
icity was assessed by counting the number of ommatidia,
ommatidia fusions and number of bristles in a represen-
tative central area of the eye for each genotype. The
number of fused ommatidia was significantly higher
for ADan, Aβ42 and ABri as compared to BRI2-23
(Figure 4B) while the number of bristles per ommatidia
was significantly lower in flies expressing the amyloid
peptides as compared to control (Figure 4C). In addition,
there was a significant loss of ommatidia in Aβ42 and
ADan-expressing lines as compared to BRI2-23 (Add-
itional file 3). Overall, the degree of toxicity reflected as
ommatidia size heterogeneity and fusion tended to be
higher for ADan and Aβ42 relative to ABri. These
phenotypes obtained with Aβ42, ABri and ADan in
our system were subtle as compared to the typical
full-rough eye as reported for flies expressing high levels
of Aβ [37]. When we compared our Aβ42 line with the
reference line Aβ42 Hj2.12, the latter presented ~2.5-fold
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Figure 3 Amyloid peptides are properly processed in Drosophila eye. RIPA-soluble proteins extracted from flies expressing two copies of
each peptide in the eye using the GMR-GAL4 driver. A, immunoreactivity with anti-His showing a very faint 3 kDa band consistent with HisBri2-23
monomer (arrowhead). B, Western blot with 6E10 showing the 4.5 kDa monomeric Aβ42 in transgenic line (arrowhead). Synthetic (sp) Aβ42 was
added to wild type Drosophila protein extract to compare molecular masses. C, immunoreactivity using anti-ABri revealed a specific band with
the expected sizes of a monomer (arrowhead); on the right, synthetic (sp) ABri peptide added to the protein extract from a non-transgenic fly.
D, Western blot using anti-ADan show the presence of a band (arrowhead) consistent with ADan monomer in the transgenic line. Wild type
Drosophila protein extract was spiked with sp ADan peptide for comparison. M, monomers. CNT, control flies (GMR-GAL4/+). In all lanes,
RIPA-soluble proteins from 15 head homogenates (150 μg) were loaded. Representative gels from more than 3 independent experiments for each
genotype are shown.
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http://www.molecularneurodegeneration.com/content/9/1/5higher Aβ42 accumulation as measured by ELISA (7.5 vs
17.5 ng/mg total protein, respectively) and a more severe
eye toxicity (Additional file 3), indicating that the “site-
directed lines” used here have relatively low levels of
expression, and yet, a toxic effect in the eye can be
detected.
In order to examine the accumulation levels of amyl-
oid peptides in vivo in a comparable way, two copies of
the His-tagged constructs were expressed in the eye
and assessed by Western blots using anti-His. As shown
in Figure 5, the reactivity of HisADan and HisAβ42
were ~4 fold and ~3 fold higher than HisABri, respectively.
To evaluate the possible effect of the His tag upon amyl-
oid peptides, transgenic lines carrying two copies of
tagged or untagged peptides were analyzed by Western
blots using amyloid-specific antibodies (Additional file 4).
In the case of HisAβ42, there was a ~3 fold increase as
compared to Aβ42 while there were no differences be-
tween ADan and HisADan. The effect upon ABri couldnot be accurately measured due to the very low signal and
high background of the blots. These results raise the pos-
sibility that, at least for ADan (for which the His tag had
no effect) its levels of accumulation may correlate with
toxicity, as suggested for Aβ42. Further in vivo and
in vitro studies may help to clarify the mechanisms by
which the His tag imposes differential effects on amyloid
peptides accumulation.
Aβ42, ABri and ADan show different patterns of
non-fibrillar deposition in the eye
Histological analysis of retina paraffin sections stained
with hematoxilin and eosin (H&E) were consistent with
the eye external phenotype, showing mild disorganization
and heterogeneity in the sizes of ommatidia in GMR-
GAL4/Aβ42, GMR-GAL4/ABri and GMR-GAL4/ADan as
compared to GMR-GAL4/ Bri2-23 (Figure 6A).
The accumulation of Aβ42, ABri and ADan in the eye
(expressing two copies of each peptide under GMR-GAL4)
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Figure 4 Differential toxicity of Aβ42, ABri and ADan in the eye. A, morphological analysis of eye integrity from flies expressing Bri2-23,
Aβ42, ABri and ADan. Top panel, ESEM microphotographs indicating the selected area (135 × 135 μm) used to count the number of ommatidia
and bristles.The area used for quantification of fused ommatidia was slightly larger (195 × 170 μm) and it is not shown for clarity. Bottom panel,
higher magnification of the selected regions as delineated in the top panel. Fused ommatidia are indicated with arrows. Bar scales, 100 μm and
50 μm for top and bottom panels, respectively. B, quantification of fused ommatidia in the selected area for each genotype. C, quantification of
bristles in the selected area for each genotype. One- way ANOVA followed by Dunnett’s comparison test analysis was performed. Eight eyes per
genotype, randomly taken from 5 independent biological experiments were analyzed. Data are expressed as mean ± SEM. Asterisks indicate
statistically significant differences (*p < 0.05, **p < 0.01).
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http://www.molecularneurodegeneration.com/content/9/1/5was studied by immunohistochemistry with specific anti-
bodies on paraffin sections of the fly heads (Figure 6B).
Specificity of staining was assessed by using 6E10, anti-
ABri and anti-ADan antibodies upon eye sections of
GMR-GAL4/Bri2-23 lines and unrelated IgG as primary
antibodies. Aβ42 staining showed deposits in the retina
following rhabdomers topology that were more abundant
toward the basal ommatidial region. ABri immunoreacti-
vity was scattered, showing discrete deposits in ommatidia
close to the lamina different from ADan distribution that
was mainly along the inner ommatidial rhabdomers with astronger immunoreactivity. Thioflavine-S (ThS) staining
of similar sections was negative for all peptides (not
shown). These findings suggest that in the Drosophila eye,
and despite similar levels of mRNA transcription, non-
fibrillar Aβ42, ABri and ADan induced different degrees
of toxicity, possibly related to different levels of accumula-
tion and distribution.
Toxicity of Aβ42, ABri and ADan in the CNS
To study Aβ42, ABri and ADan neurotoxicity in the
CNS, peptides were expressed with the pan-neuronal
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Figure 5 Analysis of His-tagged amyloid protein levels. A,
Western blots of fly head homogenates expressing two copies of
His-tagged peptides in the eye. Top panel, anti-His shows different
levels of monomeric HisAβ42, HisABri and HisADan accumulation in
transgenic flies after 10 days p.e. In this experiment, the expression
levels of HisBri2-23 were below the limit of detection. Bottom panel,
Western blot of the same membrane re-probed with anti-actin
antibody for loading normalization. B, quantification of HisAβ42 and
HisADan levels relative to HisABri. At least 3 independent experiments
were performed. A.U., arbitrary units.
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http://www.molecularneurodegeneration.com/content/9/1/5driver elav-GAL4. Lines expressing Bri2-23 were used as
negative controls and two behavioral paradigms were
tested; negative geotaxis (to evaluate locomotor coordin-
ation) and positive phototaxis (to evaluate response to
light). In the geotaxis assay, flies expressing one copy of
each transgene and kept at 25°C showed no climbing de-
fects (not shown). However, flies expressing two copies of
amyloid peptides and kept at 28°C after eclosion showed
behavioral defects that worsened with age (Figure 7A).
After 7 days p.e, ADan-expressing flies displayed a signifi-
cant impairment in climbing ability (in cm) compared to
Bri2-23 (2.5 ± 0.7 vs 4.6 ± 0.2, respectively, p < 0.001) while
in Aβ42 (4.6 ± 0.2) and ABri (3.8 ± 0.2) there was no de-
tectable toxicity. After 15 days, flies expressing ABri
showed a significant toxicity compared to Bri2-23 (2.3 ±
0.3 vs 3.8 ± 0.1 respectively, p < 0.01), while Aβ42 effect
was only evident after 21 days as compared to Bri2-23
(1.5 ± 0.3 vs 3 ± 0.2, respectively, p < 0.01). Therefore, thethree amyloid peptides were capable of causing a signifi-
cant worsening of climbing ability in the geotaxis assay.
However, Aβ42 and ABri neurotoxicity was rather mild
and strongly age-dependent, as reported for other Aβ
Drosophila models [32,33]. ADan, in turn, was highly toxic
at the first time-point analyzed. In the phototaxis assay,
flies expressing one copy of each peptide and kept at 25°C
showed that only ADan was capable of exerting a signifi-
cant impairment in 25 days-old flies (p < 0.05) reinforcing
the higher toxicity of this peptide (Figure 7B and Add-
itional file 5). These results were unlikely due to loco-
motor defects since flies expressing one copy of amyloid
peptides under the same conditions showed no deficits in
climbing assays, as mentioned above. Next, a specific
group of neurons was tested for their vulnerability to
amyloid peptides. The small and large lateral ventral neu-
rons is a key subgroup of neurons that produce the neuro-
peptide pigment dispersing factor (pdf ) and control
circadian locomotor activity. We used the pdf-GAL4
driver to direct expression of two copies of Bri2-23, ABri,
ADan and Aβ42 to these cells. Neurodegeneration of pdf-
neurons results in a dysregulation of the circadian rhythm
with aging [44]. The analysis of circadian locomotor ac-
tivity in flies expressing amyloid peptides showed nor-
mal rhythm and period both in young (5-days old)
and aged (21-days old) individuals as compared to
pdf-GAL4/ Bri2-23 or pdf-GAL4/+ (Additional file 6).
This result was interesting although not unexpected,
according to a previous report in which no circadian
behavioral phenotype was observed in pdf neurons
expressing the Arctic Aβ mutant [45]. Taken together,
our behavioral experiments point at a different vulnerabil-
ity of neuronal populations to amyloid peptides toxicity.
Histological analysis and immunostaining in the CNS
To assess the effect of amyloid accumulation on the in-
tegrity of the CNS, two copies of each peptide were
expressed under the pan-neuronal driver elav-GAL4 and
brain paraffin sections stained with H&E were examined
(Figure 8A) under light microscopy. Specifically, we
looked at the degree of vacuolization, a widely used par-
ameter of neuronal death [46,47]. Amyloid peptides ex-
pression increased vacuolization, quantified as the loss
of tissue area in cortical neurons and neuropil that was
significantly higher for Aβ42 as compared to Bri2-23
(p < 0.001) while ABri and ADan showed a non-significant
tendency (Figure 8B). Next, the accumulation of amyloid
peptides in the brain was assessed by immunohistoche-
mistry with specific antibodies using elav-GAL4/Bri2-23
flies as negative controls. In the three cases, immunostai-
ning was detected in the cortex (Figure 9). Aβ42 showed a
highly discrete and specific labeling that was consistent
with intracellular accumulation, as described [29]. ABri
and ADan distribution was much more widespread,
A BGMR-GAL4 GMR-GAL4
anti-ABri anti-ADan
Aβ42 x2 ABri x2
BRI2-23 x2 
ADan x2
anti-Aβ
  BRI2-23 x2 BRI2-23 x2 
Aβ42 x2
ABri x2 ADan x2
BRI2-23 x2
Figure 6 Accumulation of amyloid peptides in the retina. A, paraffin sections of the retina stained with H&E showing disorganization of
ommatidia (arrows). Scale bar = 25 μm. B, horizontal sections from the retina of transgenic lines: GMR-GAL4/Aβ42 × 2, GMR-GAL4/ABri × 2 and
GMR-GAL4/ADan x 2 were immunostained with 6E10, anti-ABri and anti-ADan, respectively and sections from GMR-GAL4/Bri2-23 x 2 control lines
probed with the amyloid peptide-specific antibodies. Arrows indicate immunoreactivity consistent with amyloid peptide deposits. Images
represent the results of at least 2 independent biological experiments. Scale bar = 20 μm.
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Figure 7 Age and amyloid peptide-dependent toxicity in the CNS. Pan-neuronal transgene expression was induced using the elav-GAL4
driver. A, negative geotaxis assays were performed at the indicated times with flies expressing two copies of the transgenes. The slight decline
in climbing performance with age in non-transgenic flies has been reported [reviewed in 36]. ADan expression was associated with reduced
climbing at 7 days of age while the toxic effect of ABri and Aβ42 was seen at 15 and 21 days, respectively. Climbing was expressed in cm as the
mean ± SEM. Data from 5 technical replicates from each of 3 independent biological experiments per genotype were analyzed. B, phototaxis
assays were performed at the indicated times with flies expressing one copy of each transgene. At 25 days p.e, flies expressing ADan had a lower
light response in comparison to Bri2-23, Aβ42 or ABri. Results from 2 technical replicates from each of 3 independent biological experiments per
genotype are shown. Phototaxis was expressed as the percentage (mean ± SEM) of flies that responded to light. Asterisks indicate statistically
significant differences, (*p < 0.05; ** p < 0.01; *** p < 0.001). Geotaxis and Phototaxis data were statistically analyzed by two-way repeated measures
ANOVA, followed by Bonferroni’s comparison test for all genotypes and time points which are shown in Additional file 5.
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Figure 8 Histological analysis of fly brains. A, frontal sections of 21-day-old flies were stained with H&E and examined by bright-field microscopy.
Vacuolization (>3 μm) of brain tissue was significantly higher in lines expressing Aβ42 as compared to Bri2-23, ABri and ADan. B, percentage of the area
of tissue loss expressed as mean ± SEM. All lines expressed 2 copies of each peptide and 8–10 hemispheres per genotype were used for quantification.
Asterisks indicate significant differences (One-way ANOVA, followed by Dunnett’s multiple comparison test). Scale bar = 50 μm.
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These features may explain the apparent contradiction be-
tween the extent of tissue loss and the degree of neurotox-
icity among the peptides. ABri and ADan soluble species,
with a more diffused distribution than Aβ42, may induce
an earlier synaptic dysfunction (reflected in behavioral de-
fects) in contrast to localized neuronal death. Moreover,
brain paraffin sections showing a negative staining with
ThS support the non-fibrillar form of deposition of the
three amyloid peptides (Additional file 7).
Conclusions
Our results describe a novel Drosophila model of mutant
peptides associated with human dementias, in which the
major neuropathological hallmarks are amyloid depositsAβ42 x2 
BRI2-23 x2
Paraffin horizontal section
anti-Aβ
A B
Figure 9 Specific accumulation of amyloid peptides in the Drosophila
the selected area from which immunohistochemistry is shown. B, amyloid
antibodies in lines expressing 2 copies of each transgene. Microphotograph
and more widespread ABri and ADan deposits which were detected mainl
No staining was detected in Bri2-23 line, used as a negative control for ant
experiments are shown. Scale bar = 50 μm.and neurofibrillary tangles. In the case of ADan, the fly
model may contribute to recently reported studies in
transgenic mice by increasing our understanding of the
molecular mechanism associated with ADan toxicity and
the pathogenesis of FDD. Regarding ABri, this is the first
animal model in which neurotoxicity is directly tested
in vivo.
Although low levels of expression of the transgenes
may be a drawback for an easy detection of amyloid pep-
tide accumulation, they allow a more reliable measure of
toxicity without artifacts associated with acute and high
over-expression. Importantly, despite the relatively low
levels of expression of our transgenes, we were able to
detect toxicity in the eye and in the CNS of flies. The
phenotypes, as expected, were mild as compared toelav-GAL4
ABri x2 ADan x2
BRI2-23 x2 BRI2-23 x2
anti-ABri anti-ADan
CNS. A, low magnification micrograph of brain section indicating
deposits in the CNS were assessed with specific anti-amyloid peptide
s of frontal paraffin sections showed discrete aggregates of Aβ42
y in the supraesophagical brain, both in neurons and neuropil (arrows).
ibody specificity. Representative images from 3 independent biological
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yet, sufficient to detect important similarities and differ-
ences regarding the degree of toxicity and accumulation
among Aβ42, ABri and ADan. Both in the CNS and in
the eye, ADan was more toxic than Aβ42 and ABri, pos-
sibly due to a faster rate of aggregation. In the CNS,
ABri appeared to be more toxic than Aβ42, but the rela-
tionship between peptide levels was not straightforward,
suggesting additional factors involved such as conform-
ation or differential neuronal vulnerability. The solubil-
ity, the pattern of deposition, and the fact that all
deposits in the brain and the eye were not stained by
ThS, strongly suggest that toxicity of the three amyloid
peptides was likely related to the accretion of soluble
species. Our data on the Drosophila models correlate
well with recent work on a double transgenic mouse
model for FDD, in which enhanced tauopathy, tau trun-
cation, and synaptic loss occurs prior to any detectable
ADan deposition [15].
In summary, the Drosophila lines presented in this
paper support the neurotoxicity of ABri and confirm the
toxicity of ADan and Aβ42, suggesting that this effect
may be important in the pathogenesis of human demen-
tia associated with the slow and relentless accumulation
of amyloid peptides.
Methods
Generation of transgenic lines and stocks
The Bri2-23, ABri and ADan cDNAs were obtained by
PCR from BRI2 mutant templates [14,48]. Aβ42 cDNAs
was amplified from human AβPP-CT99 fragment cloned
in pGEX. The cDNA of necrotic protein signal peptide
MASKVSILLLLTVHLLAAQTFAQ was obtained from
the pOT Nec (GH10112). The primers’ sequences and
overall strategy to generate fusion constructs are de-
scribed in Additional file 1. Constructs were subcloned
in the pUAST- attB expression vector. Transgenic flies
were obtained by injection of embryos from line ΦX-
86Fb (y w M {eGFP.vas-int. Dm} ZH-2A; +; M {RFP.
attP} ZH-86Fb; +) with constructs cloned in pUAST-
attB, and therefore integration took place at a specific
site on chromosome 3 [42]. The GMR-GAL4 and
elavc155-GAL4 lines were obtained from Bloomington
Stock Center. The Hj2.12 line was kindly provided by
Dr. Mary Konsolaki. This line has several UAS-Aβ42
randomly inserted on chromosome 2 (personal commu-
nication). All crosses and maintenance of flies were done
at 25°C or 28°C as indicated.
Peptides and antibodies
Synthetic Aβ1-42 was obtained from American Peptide
Co. Synthetic ABri was a generous gift of Prof. Jorge
Ghiso, New York University. Monoclonal anti-Aβ 6E10
was from Signet. Monoclonal antibodies anti-His wereobtained from Abcam, Cambridge, MA and Qiagen,
Valencia, CA. Polyclonal antisera anti-ADan and anti-
ABri were generated as reported before [14].
DNA extraction and PCR
Thirty flies were homogenized in 400 μl of Buffer A
(100 mM Tris–HCl, pH 7.5, 100 mM EDTA,100 mM
NaCl, 0.5% SDS) and incubated at 65°C for 30 min. Eight
hundred μl of a 5 M KOAc: 6 M LiCl (1:2.5) solution
were added and left 10 min on ice. After centrifuga-
tion at 14,000 rpm for 15 min, 700 μl of isopropanol
were added per ml of supernatant. Samples were cen-
trifuged at 14,000 rpm for 15 min, the pellet washed
with cold ethanol and resuspended in water. PCR re-
actions were done using KAPA Taq (Kapa Biosystems,
Woburn, MA) and run on a Bio-Rad cycler (Bio-Rad,
Hercules, CA). The following primers, which are described
in Additional file 1, were used: forward, Br_F1b and reverse
Br_R2 for BRI2-23, Br_R3 for ABri, Br_R5 for ADan and
R-Aβ42 for Aβ42.
RNA extraction and quantitative real time PCR analysis
For each experiment, 30–40 flies carrying two copies of
each transgene were collected and frozen. Heads were
mechanically isolated and total RNA extracted using
Trizol (Invitrogen Carlsbad, USA) according to the man-
ufacturer’s protocol. An additional centrifugation step at
11,000 × g for 10 min was used to remove the cuticles
prior to the addition of chloroform. The concentration
of total RNA purified from each sample was measured
with a Nanodrop 2000 spectrophotometer (Thermo
Scientific Walthman, MA). One to 2.5 μg of total RNA
were digested with DNAse I (Promega Madison, WI)
immediately followed by reverse transcription using the
Superscript II system (Invitrogen, Carlsbad, USA) with
oligo (dT) primers. PCR reactions were done using
KAPA SYBR* FAST qPCR Master Mix (2×) from KAPA
BIOSYSTEMS (Woburn, MA) following the manufac-
turers’ instructions. Reactions were run in an Mx3005P
Cycler (Stratagene, Santa Clara, CA). Data were ana-
lyzed using MxPRO-Mx3005P software. The primers used
for Nec-Bri2-23, Nec-ABri and Nec-ADan transgenes were
directed to: 1) the Nec sequence (forward: 5′-ATA CGA
ATT CAT GGC GAG CAA AG-3′); and 2) a common
sequence for the three peptides, C-terminal of Bri2-23
(reverse 5′-GTT TCCACG GCA AAT TTG TT-3′). For
tubulin cDNA amplification, the following primers were
used: forward 5′-GCC TGA ACA TAG CGG TGA AC-3′
and reverse 5′-ATC CCC AAC AAC GTG AAG AC-3′.
Tissue processing, SDS-PAGE and Western blots
Fly heads were homogenized in RIPA buffer (50 mM
Tris–HCl, pH 8.0, 150 mM NaCl, containing 0.5% so-
dium deoxycholate, 1% Triton X-100), 1% SDS, 5 mM
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tinin, 1 μg/ml pepstatin, 50 mM sodium fluoride and
5 mM sodium orthovanadate. After sonication, homoge-
nates were centrifuged at 14,000 rpm for 1 h. RIPA in-
soluble pellets were homogenized in 90% formic acid
(FA) followed by centrifugation as described above. FA
was evaporated by Speed Vac (Savant, SC100) and RIPA
and FA-soluble proteins were re-suspended in sample
buffer containing 0.1 M dithiothreitol. Protein extracts
were separated on 12.5 or 15% Tris-Tricine gels and
transferred onto PVDF membranes (GE Bioscience,
Piscataway, NJ). Membranes were incubated with 6E10
monoclonal antibody (1/1000), anti-ABri (1/500) anti-
ADan (1/1000) or a mixture of both monoclonal anti-
His (1/500 each Qiagen and Abcam). Anti-actin (Sigma)
was used for protein loading normalization. Immu-
noreactivity was detected with anti-rabbit or anti-mouse
horseradish peroxidase-labeled IgG (Dako Denmark) and
enhanced chemiluminescence ECL Plus (GE Bioscience
Piscataway, NJ). Immunoblots were scanned with Storm
840 and band intensities quantified with ImageQuant 5.1
software (GE Bioscience Piscataway, NJ).
Eye toxicity
Flies expressing one or two copies of the peptides in the
eye (GMR-GAL4) were raised at 25°C or 28°C and aged
for 10 days before examination under light microscope.
At least 100 eyes per genotype were analyzed from 5 in-
dependent biological experiments. Due to the high pene-
trance of phenotypes (90-100%), 8–10 eyes per genotype
were randomly selected for Environmental Scanning
Electron Microscopy (ESEM) analysis. Adult flies were
immobilized on the ESEM mount using water-based col-
loidal carbon glue for proper orientation. The electro-
scan was performed with an ESEM microscope model
XL30 (Philips) at 20.0 kV and 0.9 Torr in the auxiliary
mode. This technology did not require metal coating of
the specimen. To analyze toxicity in a quantitative man-
ner, eyes were properly oriented and a comparable area
for each genotype was selected. The number of omma-
tidia, fused ommatidia and bristles were also counted in
the selected areas. Eight fly eyes were analyzed per geno-
type. All the counting and measurements were done as
blind experiments.
Histology and immunostaining
Fly heads were fixed in Carnoy solution (60% ethanol,
30% chloroform, 10% acetic acid) at 4°C overnight and
dehydrated in ethanol. Samples were treated for 30 min
with butanol:ethanol (1:1), butanol:toluene (1:1), toluene,
and finally soaked in toluene: paraffin (1:1) for 30 min at
65°C. After incubation for 2 h in pure paraffin, heads
were embedded and cut in 7-μm serial frontal sections.
After H&E staining, images were captured using anOLYMPUS B × 50 Microscope and analyzed with the
Image Pro Plus software (Media Cybernetics). Neurode-
generation was quantified and reported as the percent-
age of area lost in the tissue. The ratio was calculated by
dividing the area of vacuolization (each vacuole with a
diameter of at least 3 μm) by the total area of the brain
section. At least 8 brains per genotype were analyzed.
ThS staining was used for the detection of amyloid fi-
brillar deposits. The tissue was deparaffinized and incu-
bated in 50% ethanol containing 1% ThS (Sigma St.
Louis, MO) for 20 min. After washing in 50% ethanol
and PBS, tissue sections were analyzed using a confocal
Zeiss LSM510 microscope. Immunostaining was per-
formed by incubating sections with anti-Aβ monoclonal
6E10 (1/500) and protein A-sepharose affinity-purified
anti-ADan and anti-ABri antibodies (1/100). Immunore-
activity was detected with biotinylated anti-mouse or
anti-rabbit IgG followed by incubation with avidin–
biotin complex (Vector Laboratories, Burlingame, CA).
The reaction products were visualized with 0.05% diamino-
benzidine tetrahydrochloride, 0.01% hydrogen peroxide
and, in some cases with nickel enhancement. Negative
controls included incubation with primary unrelated
antibodies and immunostainig of GAL4/Bri2-23 fly sections
with amyloid peptides-specific antibodies.
Climbing assay (rapid iterative negative geotaxis, RING)
Flies expressing one or two copies of Bri2-23, Aβ42, ABri
and ADan peptides in the CNS (with elav-GAL4) were
raised at 25°C and incubated at 28°C in groups of 40
males in 4-inch glass vials with food replacement every
3–4 days. Vertical mobility was tested using the RING
assay as described [49]. Briefly, the day before the assay
10 males per genotype were randomly selected under
CO2. The following day, each group was transferred into
empty vials without anesthesia and the vials were loaded
into the RING apparatus. The apparatus was tapped
three times in rapid succession to initiate a negative geo-
taxis response. After 4 sec, digital images were taken.
The climbed distance in cm was measured for each fly
and the average height per genotype calculated using the
Scion Image software. Data from 5 technical replicates
from each of 3 independent biological experiments per
genotype were analyzed.
Phototaxis assay
Flies expressing one copy of Bri2-23, Aβ42, ABri and
ADan in the CNS (with elav-GAL4) were raised and
kept at 25°C. Phototaxis was performed as described
[44]. Briefly, the day before the assay, 30 males per geno-
type were randomly selected under CO2. The following
day, 15 min before testing, flies were transferred to dark-
ness. Further manipulations were performed under red
light. For the assay, flies were transferred to empty tubes
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ting tube which had a white cold light at the end of it.
The number of flies that moved to the collecting tube,
towards the light (defined as a positive response) was
counted and the results were expressed as the percen-
tage of flies that responded to light of the total number
of animals per assay. Data from 2 technical replicates
from each of 3 independent biological experiments per
genotype were analyzed.
Circadian locomotor activity
Fly activity was monitored as described [44]. Briefly,
newly eclosed male flies were trained under 12 h light-
darkness (LD) cycles until the beginning of the experi-
ment. Then, young (5 days-old) and aged (21 days-old)
flies were placed in glass tubes and monitored for activ-
ity with infrared detectors. Fly activity was monitored
under LD conditions for 3 days and then released into
constant darkness (DD) for at least one week employing
commercially available activity monitors (TriKinetics,
Waltham, MA). Period and rhythmicity were estimated
using the ClockLab software (Actimetrics, Evanston, IL)
from data collected under DD. Each experiment was re-
peated at least two times from two independent bio-
logical replicates.
ELISA
Five fly heads from our line GMR/Aβ42 carrying two copies
of the transgene and 5 heads from the GMR/Hj2.12 line were
homogenized and proteins extracted in 50 mM Tris–HCl,
pH 8 containing 5 M guanidine and a cocktail of proteases
inhibitors (Sigma St. Louis, MO). After centrifugation at
10,000 × g, proteins in the supernatant were quantified using
a bicinchoninic acid kit (Thermo Scientific, Rockford, IL).
Aβ42 concentration was determined using a commercial
capture ELISA kit (Invitrogen Frederick, MD) following
the manufacturer’s instructions.
Statistical analysis
Data were analyzed by Student’s t-test, One-way ANOVA,
and Two-way repeated measures ANOVA, followed by
post-hoc tests. Graph Pad Prism v.5 software was used.
Statistical results were presented as means ± SEM. Aster-
isks indicate levels of significance (*p <0.05, **p <0.01
and ***p < 0.001).
Additional files
Additional file 1: Primers used for constructs generation. Table with
the sequences of all primers used in this study and PCR strategy.
Additional file 2: Western blots of amyloid peptides in SDS-insoluble
factions from Drosophila eyes. Accumulation of Aβ42 and ADan in the
formic acid-soluble fraction. Non-specific immunoreactive bands in Western
blots from RIPA-soluble homogenates.Additional file 3: Toxicity in the Drosophila eye. Toxicity of GMR-GAL/+
as compared to GMR-GAL4/Bri2-23 lines at 28°C for 10 days; dose dependent
Aβ42 toxicity in the eye and number of ommatidia in transgenic vs
non-transgenic lines.
Additional file 4: Accumulation of untagged and His-tagged amyloid
peptides. Western blot anti specific peptides from fly heads expressing
tag and untagged peptides.
Additional file 5: Geotaxis and Phototaxis statistical analysis. Two-way
repeated measures ANOVA, followed by comparison tests for all
genotypes and time points.
Additional file 6: pdf-neurons are resistant to amyloid peptides
toxicity. Figure showing the circadian locomotor activity of transgenic
flies.
Additional file 7: Thioflavine S-negative accumulation of Aβ, ABri
and ADan in the CNS of Drosophila. Figure showing negative
Thioflavine-S staining of brain sections from Drosophila transgenic lines.
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